• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Nuvation Bio (NUVB) Following SIGMA Trial Expansion Still Looks Cheap Versus Fair Value

    Simply Wall St·11/01/2026 04:42:46
    语音播报

    What the SIGMA trial expansion means for Nuvation Bio stock

    Nuvation Bio (NUVB) is back in focus after the company said its pivotal Phase 3 SIGMA trial of safusidenib will widen into six additional European countries, expanding the study's global footprint.

    The SIGMA expansion lands at a time when Nuvation Bio’s share price has slipped 7.39% over the past 30 days and 22.73% over 90 days. However, the 3-year total shareholder return is very large, signalling long term backing even as near term momentum has faded.

    Compare Nuvation Bio’s setup with other cancer treatment specialists moving on fresh clinical catalysts by scanning the hand-picked 34 healthcare AI stocks now.

    Bulls view Nuvation Bio as a discounted way to gain exposure to a late-stage oncology pipeline after the SIGMA expansion. Bears highlight recent share price weakness and ongoing losses. Which side does the current valuation lean toward?

    Most Popular Narrative: 64% Undervalued

    Compared with the most followed fair value estimate of $13.11, Nuvation Bio’s last close at $4.76 sits at a steep discount, which places significant importance on how its core cancer programs develop.

    Advancement of safusidenib into a pivotal Phase III high grade IDH1 mutant glioma maintenance study, targeting a population underserved by existing therapies, could position the company to tap into a durable brain tumor market and add a second meaningful revenue pillar that has the potential to scale earnings beyond IBTROZI.

    See why 9 investors see Nuvation Bio as 64% undervalued.

    Result: Fair Value of $13.11 (UNDERVALUED)

    Still, the narrative around Nuvation Bio could shift quickly if safusidenib timelines slip or if competing ROS1 therapies pressure IBTROZI expectations and related projections.

    Find out about the key risks to this Nuvation Bio narrative.

    Next Steps

    If the bullish tone around Nuvation Bio feels compelling but not conclusive, consider promptly testing that optimism against the underlying data. Start by checking the 2 key rewards.

    Looking for more investment ideas beyond Nuvation Bio?

    Do not stop at a single ticker when the wider market may hold better fits for your goals and risk limits. Let a focused screener shortlist candidates built around clear fundamentals, then decide where your next round of research should go.